SELLAS Life Sciences Group, Inc. (SLS) Debt Components
- 2018-12-31: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD (m).
- 2018-09-30: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $76.00K; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $100.00K.
- 2018-06-30: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $7.78M; Long-term Debt, Excluding Current MaturitiesUSD $0.00; Long-term DebtUSD $7.80M.
- 2018-03-31: Convertible Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $8.53M; Long-term Debt, Excluding Current MaturitiesUSD $1.15M; Long-term DebtUSD $9.70M.
SELLAS Life Sciences Group, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-term Debt, Gross USD | Debt, Long-term and Short-term, Combined Amount USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-12-31 | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $76.00K | $0.00 | $100.00K | (m) | (m) | (m) | (m) | $76.00K | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.78M | $0.00 | $7.80M | (m) | (m) | (m) | (m) | $7.78M | $6.90M | (m) | (m) |
| 2018-03-31 | (m) | $8.53M | $1.15M | $9.70M | (m) | (m) | (m) | (m) | $9.68M | $8.00M | (m) | (m) |
| 2017-12-31 | (m) | $8.38M | $2.61M | (m) | (m) | (m) | (m) | (m) | $10.99M | $10.20M | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | $10.99M | (m) | (m) | (m) | $10.20M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $12.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $11.97M | (m) | $198.36K |
| 2017-06-30 | (m) | $13.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.17M | (m) | $146.55K |
| 2017-03-31 | (m) | $12.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $13.17M | (m) | $575.00K |
| 2016-12-31 | (m) | $16.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $17.62M | (m) | $1.22M |
| 2016-09-30 | (m) | $23.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $23.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $3.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $4.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $0.00 | (m) | $4.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $4.17M | $1.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $4.08M | $2.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.99M | $3.53M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $3.91M | $4.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | $8.16M | $3.91M | $4.25M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $4.16M | $5.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $4.08M | $6.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $3.10M | $6.88M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $2.15M | $7.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | $10.00M | $2.15M | $3.94M | $3.91M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $1.22M | $8.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $301.00K | $9.40M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-05-08 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.45% | (m) |
| 2013-05-08 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $15.00M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $500.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | $500.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |